Division of Endocrinology, Department of Clinical Medicine, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy.
J Clin Endocrinol Metab. 2010 Oct;95(10):E204-8. doi: 10.1210/jc.2010-0145. Epub 2010 Jul 21.
The determinants of the variability in the clinical response to metformin in women with the polycystic ovary syndrome (PCOS) are enigmatic. Organic cation transporter 1 (OCT1) plays a trigger role in the hepatic uptake of metformin. In cellular studies, it was recently shown that seven polymorphisms of OCT1 exhibit reduced transport of metformin. It is noteworthy that four of the seven variants, R61C (C>T), G401S (G>A), G465R (G>A), and 420del, are present in individuals of European descent.
The aim was testing the hypothesis that polymorphisms in OCT1 may contribute to the variability in the response to metformin in PCOS.
We conducted a prospective study at an academic hospital.
We studied 150 Italian PCOS patients aged 18-45 yr.
We administered two oral doses of metformin per day for 6 months.
We measured the genotype distribution of R61C, G401S, G465R, and 420del and the influence of genotypes on response to metformin.
Eighty-four PCOS women had the reference allele at all four positions and were classified as "References," whereas 66 PCOS women carried at least one copy of the four polymorphisms (52 carried one polymorphism, 13 carried two polymorphisms, and one carried three polymorphisms) and were classified as "Variants." Only the References reduced their total cholesterol [-14 mg/dl (-22 to -5); P = 0.002] and triglycerides [-17 mg/dl (-29 to -5); P = 0.008]. Insulin(AUC) decreased in References and in Variants carrying one polymorphism, but it did not change in Variants carrying two or more polymorphisms.
Genetic variation in OCT1 may be associated with heterogeneity in the metabolic response to metformin in women with PCOS.
多囊卵巢综合征(PCOS)女性对二甲双胍临床反应的可变性的决定因素尚不清楚。有机阳离子转运蛋白 1(OCT1)在二甲双胍的肝脏摄取中起触发作用。在细胞研究中,最近表明 OCT1 的七种多态性表现出二甲双胍转运减少。值得注意的是,这七种变体中的四种,R61C(C>T)、G401S(G>A)、G465R(G>A)和 420del,存在于欧洲血统的个体中。
本研究旨在检验假设,即 OCT1 多态性可能导致 PCOS 患者对二甲双胍反应的变异性。
我们在一家学术医院进行了一项前瞻性研究。
我们研究了 150 名年龄在 18-45 岁的意大利 PCOS 患者。
我们每天给予二甲双胍两次口服,持续 6 个月。
我们测量了 R61C、G401S、G465R 和 420del 的基因型分布以及基因型对二甲双胍反应的影响。
84 名 PCOS 女性在所有四个位置均携带参考等位基因,被归类为“参考”,而 66 名 PCOS 女性携带至少一种四种多态性的副本(52 名携带一种多态性,13 名携带两种多态性,一名携带三种多态性),被归类为“变体”。只有参考组降低了总胆固醇[-14mg/dl(-22 至-5);P=0.002]和甘油三酯[-17mg/dl(-29 至-5);P=0.008]。参考组和携带一种多态性的变体组胰岛素(AUC)降低,但携带两种或更多多态性的变体组胰岛素未发生变化。
OCT1 中的遗传变异可能与 PCOS 女性对二甲双胍代谢反应的异质性相关。